english

Programme des séminaires externes de l'IRCM

Lieu : IRCM, salle de conférences, bâtiment 3, rez-de-chaussée

Contact : charles.theillet@inserm.fr
Téléphone : 04 67 61 37 66

Vendredi 28 avril 2017, 14h00

Charles Geminard, institut de Biologie Valrose (iBV), CNRS/INSERM, Nice

 

“Left-Right asymmetry in Drosophila”

 

Contact : alexandre.djiane@inserm.fr

Vendredi 12 mai 2017, 14h00

Arnaud Vigneron, CRCM, Centre Léon Bérard, Université Lyon 1

 

"Metabolic hormones link the stemness features of mammary cancer cells to their neoplastic transformation"

 

Contact : laurent.lecam@inserm.fr

 

Vendredi 2 juin 2017, 14h00

Pierre-Antoine Defossez, CNRS UMR7216, Université Paris 7

 

“Functions of methyl-DNA binding proteins in normal cells and in cancer"

 

Contact : claude.sardet@inserm.fr

 

Vendredi 9 juin 2017, 11h00

Conférence de "IRCM-SIRIC Montpellier-Cancer seminar series"

 

Prof. Erwin Wagner, CNIO, Madrid.

 

"Stress signaling in Inflammation and Cancer"

 

Contact : piona.dariavach@icm.unicancer.fr

 

résumé :

Our studies aim to analyze gene function in healthy and pathological conditions, e.g. in tumour development, using the mouse as a model organism, but also employing patient-derived samples. Specifically, the functions of the AP-1 (Fos/Jun) transcription factor complex regulating cell proliferation, differentiation and oncogenesis, as well as the cross-talk between organs are being investigated. The goal is to define molecular pathways leading to disease/cancer development and to identify novel therapeutic targets. We focus on elucidating a causal link between inflammation, cancer and AP-1 (Fos/Jun) expression using cell type-specific, switchable genetically engineered mouse models. We are also developing and characterizing new GEMMs for cancer and human diseases, such as for bone loss, fibrosis and psoriasis, and applying these to preclinical studies.

 

I will focus in my talk on recent studies towards understanding liver and skin pathologies at the cross-road between inflammation, metabolism and cancer, and will discuss the adverse effects of cancer cachexia, a deadly wasting syndrome and metabolic impairment with systemic manifestations frequently observed in cancer patients.

Vendredi 8 septembre 2017, 14h00

Prof. Yohei Shimono, Molecular and Cellular Biology, Kobe University, Japon

 

"Breast cancer stem cells and their metastatic dormancy: going deep into ‘Shogun’ Territory"

 

Résumé :

By analyzing surgical specimens of human breast cancer patients, we found that a set of miRNAs are differentially expressed between breast cancer stem cells and non-tumorigenic cancer cells. Among them, we found that miR-200c, miR-142 and miR-150 function as epigenetic regulators of cancer stem cells in human breast cancers. Then, we analyzed metastatic cancer stem cells using a patient-derived tumor xenograft as a model. Our results showed that metastatic cancer stem cells are in a relatively dormant state characterized by the downregulation of chemokine receptor CXCR4.

 

Finally, to find target protein for cancer stem cells, we compared the expression profiles of proteins between breast cancer stem cells and non-tumorigenic cancer cells isolated from patient tumors and patient-derived tumor xenografts in our collaborative research project. We envision that the therapies targeting cancer stem cells and metastatic cancer stem cells will become novel strategies in future to strive to cure breast cancer patients.

 

Contact: andrei.turtoi@inserm.fr

 

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Conception : ID Alizés